Control of pharmacokinetic profiles of drug-macromolecule conjugates

Advanced Drug Delivery Reviews

Volumn 19, Issue 3, 1996, Pages 377-399

  Takakura, Yoshinobu ^a   Mahato, Ram I ^a   Nishikawa, Makiya ^a   Hashida, Mitsuru ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Antitumor drugs; DNA drugs; Macromolecular conjugate; Pharmacokinetics; Protein drugs; Targeting

Indexed keywords

CONTROLLED DRUG DELIVERY; DNA; GENES; HEMODYNAMICS; MACROMOLECULES; MOLECULAR WEIGHT DISTRIBUTION; PHARMACOKINETICS; PROTEINS;

ANTISENSE OLIGONUCLEOTIDES; ANTITUMOR DRUGS; MACROMOLECULAR CONJUGATION; TARGETING;

DRUG PRODUCTS;

ALBUMIN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ASIALOFETUIN; ASIALOOROSOMUCOID; CARBOXYMETHYLDEXTRAN; CHITIN; CHITOSAN; COPOLYMER; DEXTRAN; DNA; DRUG CARRIER; GLOBULIN; INULIN; MACROGOL; MITOMYCIN C; NEOGLYCOPROTEIN; PLASMID DNA; POLYASPARTIC ACID; POLYLYSINE; POLYVINYL ALCOHOL; PROTEIN; PULLULAN; STYRENE MALEIC ANHYDRIDE COPOLYMER; SUPEROXIDE DISMUTASE; UNINDEXED DRUG; ZINOSTATIN;

CELL LEVEL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISPOSITION; DRUG STRUCTURE; DRUG TARGETING; HUMAN; MACROMOLECULE; NONHUMAN; PHARMACEUTICS; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; TECHNIQUE; TISSUE LEVEL;

EID: 0030580955     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-409X(96)00010-5     Document Type: Review

References (108)

1. [1] Sezaki, H. and Hashida, M. (1984) Macromolecule-drug conjugates in targeted cancer chemotherapy. CRC Crit. Rev. Ther. Drug Carrier Syst. 1, 1-38.
2. [2] Sezaki, H., Takakura, Y. and Hashida, M. (1989) Soluble macromolecular carriers for the delivery of antitumor drugs. Adv. Drug Del. Rev. 3, 247-266.
3. [3] Takakura, Y. and Hashida, M. (1995) Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs. Crit. Rev. Oncol. Hematol. 18, 207-231.
4. [4] Tomlinson, E. (1983) Microsphere delivery systems for drug targeting and controlled release. Int. J. Pharm. Tech. Prod. Mfr. 4, 49-57.
5. [5] Widder, K.J., Senyei, A.E. and Ranney, D.F. (1977) Magnetically responsive microspheres and other carriers for the biophysical targeting of antitumor agents. Adv. Pharmacol. Chemother. 16, 213-271.
6. [6] Taylor, A.E. and Granger, D.N. (1983) Equivalent pore modeling vesicles and channels. Federation Proc. 42, 2440-2445.
7. [7] Wisse, E. and De Leeuw, A.M. (1984) Structural elements determining transport and exchange processes in the liver. In: S.S. Davis, L. Illum, J.G. McVie and E. Tomlinson (Eds.), Microsphere and Drug Therapy: Pharmaceutical, Immunological and Medical Aspects. Elsevier, Amsterdam, pp. 1-23.
8. [8] Nishida, K., Mihara, K., Takino, T., Nakane, S., Takakura, Y., Hashida, M. and Sezaki, H. (1991) Hepatic disposition characteristics of electrically charged macromolecules in rat in vivo and in the perfused liver. Pharm. Res. 8, 437-444.
9. [9] Takakura, Y., Fujita, T., Furitsu, H., Nishikawa, M., Sezaki, H. and Hashida, M. (1994) Pharmacokinetics of succinylated proteins and dextran sulfate in mice: implications for hepatic targeting of protein drugs by direct succinylation via scavenger receptors. Int. J. Pharm. 105, 19-29.
10. [10] Kawabata, K., Takakura, Y. and Hashida, M. (1995) The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharm. Res. 12, 825-830.
11. [11] Takakura, Y., Fujita, T., Hashida, M and Sezaki, H. (1990) Disposition characteristics of macromolecules in tumor-bearing mice. Pharm. Res. 7, 339-346.
12. [12] Miyao, T., Takakura, Y., Akiyama, T., Yoneda, F., Sezaki, H. and Hashida, M. (1995) Stability and pharmacokinetic characteristics of oligonucleotides modified at terminal linkages in mice. Antisense Res. Dev. 5, 115-121.
13. [13] Perales, J.C., Ferkol, T., Molas, M. and Hanson, R.W. (1994) An evaluation of receptor-mediated gene transfer using synthetic DNA-ligand complexes. Eur. J. Biochem. 226, 255-266.
14. [14] Lee, Y.C., Stowell, C.P. and Krantz, M.K. (1976) 2-Imino-2-methoxyethyl-1-thioglycosides: new reagents for attaching sugars to proteins. Biochemistry 15, 3956-3963.
15. [15] Jain, R.K. (1987) Transport of molecules in the tumor interstitum: a review. Cancer Res. 47, 3039-3051.
16. [16] Maeda, H. and Matsumura, Y. (1989) Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst. 6, 193-210.
17. [17] Seymour, L.W. (1992) Passive tumor targeting of soluble macromolecules and drug conjugates. Crit. Rev. Ther. Drug Carrier Syst. 9, 135-187.
18. [18] Yuan, F., Leunig, M., Huang, S.K., Berk, D.A., Papahadjopoulos, D. and Jain, R.K. (1994) Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 54, 3352-3356.
19. [19] Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D.A., Torchilin, V.P. and Jain, R.K. (1995) Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55, 3752-3756.
20. [20] Takakura, Y, Takagi, A., Hashida, M. and Sezaki, H. (1987) Disposition and tumor localization of mitomycin C-dextran conjugates in mice. Pharm. Res. 4, 293-300.
21. [21] Noguchi, A., Takahashi, T., Yamaguchi, T., Kitamura, K., Takakura, Y., Hashida, M. and Sezaki, H. (1990) Tumor localization and in vivo antitumor activity of the immunoconjugate composed of anti-human colon cancer monoclonal antibody and mitomycin C-dextran conjugate. Jpn. J. Cancer Res. 82, 219-226.
22. [22] Sung, C., Youle, R.J. and Dedrick, R.L. (1990) Pharmacokinetic analysis of immunotoxin uptake in solid tumors: role of plasma kinetics, capillary permeability, and binding. Cancer Res. 50, 7382-7392.
23. [23] Kojima, T., Hashida, M., Muranishi, S. and Sezaki, H. (1980) Mitomycin C-dextran conjugate: a novel high molecular weight prodrug of mitomycin C. J. Pharm. Pharmacol. 32, 30-34.
24. [24] Takakura, Y., Kitajima, M., Matsumoto, S., Hashida, M. and Sezaki, H. (1987) Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge. I. Physicochemical characteristics and in vivo and in vitro antitumor activities. Int. J. Pharm. 37, 135-143.
25. [25] Hashida, M., Takakura, Y., Matsumoto, S., Sasaki, H., Kato, A., Kojima, T., Muranishi, S. and Sezaki, H. (1983) Regeneration characteristics of mitomycin C-dextran conjugate in relation to its activity. Chem. Pharm. Bull. 31, 2055-2063.
26. [26] Takakura, Y., Matsumoto, S., Hashida, M. and Sezaki, H. (1984) Physicochemical properties and antitumor activities of polymeric prodrugs of mitomycin C with different regeneration rates. J. Control. Rel. 10, 97-105.
27. [27] Duncan, R., Koepeckova, P., Strohalm, J., Hume, I.C., Lloyed, J.B. and Kopeck, J. (1988) Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukemia. Br. J. Cancer 57, 147.
28. [28] Duncan, R. and Spreafico, F. (1994) Polymer conjugates. Pharmacokinetic considerations for design and development. Clin. Pharmacokin. 27, 290-306.
29. [29] Yokoyama, M., Okano, T., Sakurai, Y., Ekimoto, H., Sibazaki, C. and Kataoka, K. (1991) Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. Cancer Res. 51, 3229-3236.
30. [30] Ohkouchi, K., Imoto, H., Takakura, Y., Hashida, M. and Sezaki, H. (1990) Disposition of anticancer drugs after bolus arterial administration in a tissue-isolated tumor perfusion system. Cancer Res. 50, 1640-1644.
31. [31] Imoto, H., Sakamura, Y., Ohkouchi, K., Atsumi, R., Takakura, Y., Sezaki, H. and Hashida, M. (1992) Disposition characteristics of macromolecules in the perfused tissue-isolated tumor preparation. Cancer Res. 52, 4396-4401.
32. [32] Gullino P.M. and Grantham, F.H. (1961) Studies on the exchange of fluids between host and tumor. I. A method for growing "tissue-isolated" tumor in laboratory animals. J. Natl. Cancer Inst. 27, 679-689.
33. [33] Gullino, P.M. (1970) Techniques for the study of tumor physiology. In: H. Busch (Ed.) Methods in Cancer Research. Academic Press, New York, pp. 45-91.
34. [34] Kristjansen, P.E.G., Roberge, S., Lee, I. and Jain, R.K. (1994) Tissue-isolated human tumor xenografts in athymic nude mice. Microvascular Res, 48, 389-402.
35. [35] Hamberg, L.M., Kristjansen, P.E.G., Hunter, G.J., Wolf, G.L. and Jain, R.K. (1994) Spatial heterogeneity in tumor perfusion measured with functional computed tomography at 0.05 μ1 Resolution. Cancer Res. 54, 6032-6036.
36. [36] Honda, K., Satomura, K., Hashida, M. and Sezaki, H. (1985) Topical application of mitomycin C conjugated with dextran (MMC-D): a high molecular weight derivative of mitomycin C. Jpn. J. Cancer Chemother. 12, 530-535.
37. [37] Satomura, K., Honda, K., Arimoto, A., Kikuchi, S., Sezaki, H. and Hashida, M. (1985) Surgical chemotherapy using mitomycin C-dextran conjugate. Ther. Res. 2, 311-317.
38. [38] Kennedy, K.A., Rockwell, S. and Sartorelli, A.C. (1980) Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic cells. Cancer Res. 40, 2356-2360.
39. [39] Yoffey, J.M. and Courtice, F.C. (1971) The formation of lymph. In: J.M. Yoffey and F.C. Courtice (Eds.), Lymphatics, Lymph and The Lymphomyeloid Complex. Academic Press, New York, pp. 64-159.
40. [40] Takakura, Y., Matsumoto, S., Hashida, M. and Sezaki, H. (1984) Enhanced lymphatic delivery of mitomycin C conjugated with dextran. Cancer Res. 44, 2505-2510.
41. [41] Takakura, Y., Mori, K., Hashida, M. and Sezaki, H. (1986) Absorption characteristics of macromolecular prodrugs of mitomycin C following intramuscular administration. Chem. Pharm. Bull. 34, 1775-1783.
42. [42] Takakura, Y., Atsumi, R., Hashida, M. and Sezaki, H. (1987) Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge. II. Disposition and pharmacokinetics following intravenous and intramuscular injection. Int. J. Pharm. 37, 145-154.
43. [43] Fiume, L., Busi, C., Di Stefano, G. and Mattioli, A. (1994) Targeting of antiviral drugs to the liver using glycoprotein carriers. Adv. Drug Del. Rev, 14, 51-65.
44. [44] Fiume, L., Busi, C., Corzani, S., Di Stefano, G., Gervasi, G.B. and Mattioli, A. (1994) Organ distribution of a conjugate of adenosine arabinoside monophosphate with lactosaminated albumin in rat. J. Hepatol. 20, 681-2.
45. [45] Torrani Cerenzia, M.R., Fiume, L., Busi, C., Mattioli, A., Di Stefano, G., Geravasi, G.B., Brunetto, M.R., Piantino, P., Verme, G. and Bonino, F. (1994) Inhibition of hepatitis B virus replication by adenine arabinoside monophosphate coupled to lactosaminated albumin. Efficacy, minimal effective dose and plasma clearance of conjugate. J. Hepatol. 20, 307-309.
46. [46] Nishikawa, M., Kamijyo, A., Fujita, T., Takakura, Y., Sezaki, H. and Hashida, M. (1993) Synthesis and pharmacokinetics of a new liver-specific carrier, glycosylated carboxymethyl-dextran, and its application to drug targeting. Pharm. Res. 10, 1253-1261.
47. [47] Nishikawa, M., Hirabayashi, H., Takakura, Y. and Hashida, M. (1995) Design for cell-specific targeting of proteins utilizing sugar-recognition mechanism: effect of molecular weight of proteins on targeting efficiency. Pharm. Res. 12, 209-214.
48. [48] Hirabayashi, H., Nishikawa, M., Takakura, Y. and Hashida, M. (1996) Development and pharmacokinetics of galactosylated poly(L-glutamic) acid as a biodegradable carrier for liver-specific drug delivery. Pharm. Res. in press.
49. [49] Nishikawa, M., Miyazaki, C., Yamashita, F., Takakura, Y. and Hashida, M. (1995) Galactosylated proteins are recognized by the liver according to the surface density of galactose moieties. Am. J. Physiol. 268, G849-G856.
50. [50] Jansen, R.W., Molema, G., Ching, T.L., Oosting, R., Harms, G., Moolenaar, F., Hardonk, M.J. and Meijer, D.K.F. (1991) Hepatic endocytosis of various types of mannose-terminated albumins: What is important, sugar recognition, net charge of the combination of these features. J. Biol. Chem. 266, 3343-3348.
51. [51] Takagi, A., Masuda, H., Takakura, Y. and Hashida, M. (1995) Disposition characteristics of recombinant human interleukin-II after a bolus intravenous administration in mice. J. Pharmacol. Exp. Ther. 275, 537-543.
52. [52] Fujita, T., Takakura, Y., Sezaki, H. and Hashida, M. (1995) Control of disposition characteristics of proteins by direct cationization in mice. Pharm. Sci. 1, 371-375.
53. [53] Mihara, K., Mori, M., Hojo, T., Takakura, Y., Sezaki, H. and Hashida, M. (1993) Disposition characteristics of model macromolecules in the perfused rat kidney. Biol. Pharm. Bull. 16, 158-162.
54. [54] Mihara, K., Sawai, K., Takakura, Y. and Hashida, M. (1994) Manipulation of renal disposition of human recombinant superoxide dismutase by chemical modification. Biol. Pharm. Bull. 17, 296-301.
55. [55] Takakura, Y., Mihara, K. and Hashida, M. (1994) Control of the disposition profiles of proteins in the kidney via chemical modification. J. Control. Rel. 28, 111-119.
56. [56] Franssen, E.J.F., Moolenaar, F., Zeeuw, D.D. and Meijer, D.K.F. (1994) Drug targeting to the kidney with low-molecular-weight proteins. Adv. Drug. Del. Rev. 14, 67-88.
57. [57] Fuertges, F. and Abuchowski, A. (1990) The clinical efficacy of poly(ethylene glycol)-modified proteins. J. Control, Rel. 11, 139-148.
58. [58] Katre, N.V. (1993) The conjugation of proteins with polyethylene glycol and other polymers: Altering properties of proteins to enhance their therapeutic potential. Adv. Drug. Del. Rev. 10, 91-114.
59. [59] Tanaka, H., Satake-Ishikawa, R., Ishikawa, M., Matsuki, S. and Asano, K. (1991) Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats. Cancer Res. 51, 3710-3714.
60. [60] Tsutsumi, Y., Kihara, T., Yamamoto, S., Kubo, K., Nakagawa, S., Miyake, M., Horisawa, Y., Kanamori, T., Ikegami, H. and Mayumi, T. (1994) Chemical modification of natural human tumor necrosis factor-α with polyethylene glycol increases its anti-tumor potency. Jpn. J. Cancer Res. 85, 9-12.
61. [61] Inoue, M., Ebashi, I., Watanabe, N. and Morino, Y. (1989) Synthesis of a superoxide dismutase derivative that circulates bound to albumin and accumulates in tissues whose pH is decreased. Biochemistry 28, 6619-6624.
62. [62] Fujita, T., Nishikawa, M., Tamaki, C., Takakura, Y., Hashida, M. and Sezaki, H. (1992) Targeted delivery of human superoxide dismutase by chemical modification with mono-and polysaccharide derivatives. J. Pharmacol. Exp. Ther. 263, 971-978.
63. [63] Fujita, T., Furitsu, H., Nishikawa, M., Takakura, Y., Sezaki, H. and Hashida, M. (1992) Therapeutic effect of superoxide dismutase derivatives modified with monoor polysaccharides on hepatic injury induced by ischemia/reperfusion. Biochem. Biophys. Res. Commun. 189, 191-196.
64. [64] Mihara, K., Oka, Y., Sawai, K., Takakura, Y. and Hashida, M. (1994) Improvement of therapeutic effect of human recombinant superoxide dismutase on ischemic acute renal failure in the rat via cationization and conjugation with polyethylene glycol. J. Drug Target. 2, 317-321.
65. [65] Hashida, M., Nishikawa, M., Yamashita, F. and Takakura, Y. (1994) Targeted delivery of protein drugs by chemical modification. Drug Dev. Ind. Pharm. 20, 581-590.
66. [66] Takakura, Y., Masuda, S., Tokuda, H., Nishikawa, M. and Hashida, M. (1994) Targeted delivery of superoxide dismutase to macrophages via mannose receptor-mediated mechanism. Biochem. Pharmacol. 47, 853-858.
67. [67] Schereir, H. (1994) The new frontier: gene and oligonucleotide therapy. Pharm. Acta Helv. 68, 145-159.
68. [68] Wagner, R.W. (1994) Gene inhibition using antisense oligodeoxynucleotides. Nature 372, 333-335.
69. [69] Gura, T. (1995) Antisense has growing pains. Science 270, 575-577.
70. [70] Stein, C.A. (1995) Does antisense exist? Nature Medicine 1, 1119-1121.
71. [71] Wolff, J.A., Malone, R.W., Williams, P., Chong, W., Acsadi, G., Jani, A. and Felgner, P.L. (1990) Direct gene transfer into mouse muscle in vivo. Science 247, 1465-1468.
72. [72] Acsadi, G., Jiao, S., Jani, A., Duke, D., Williams, P., Chong, W. and Wolf, J. (1991) Direct gene transfer and expression into rat heart in vivo. New Biol. 3, 71-81.
73. [73] Yovandich, J., O'Malley, Jr., B., Sikes, M. and Ledley, F.D. (1995) Gene expression to synovial cells by intraarticular administration of plasmid DNA. Hum. Gene Ther. 6, 603-610.
74. [74] Hickman, M.A., Malone, R.W., Lehmann-Bruinsma, K., Sih, T.R., Knoell, D., Szoka, F.C., Walzem, R., Carlson, D.M. and Powell, J.S. (1994) Gene expression following direct injection of DNA into liver. Hum. Gene Ther. 5, 1477-1483.
75. [75] Agrawal, S., Temsamani, J. and Tang, J.A. (1991) Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. U.S.A. 88, 7595-7599.
76. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. 267, 1181-1190.
77. [77] Rappaport, J., Hanss, B., Kopp, J.B., Copeland, T.D., Bruggeman, L.A., Coffman, T.M. and Klotman, P.E. (1995) Transport of phosphorothioate oligonucleotides in kidney: Implications for molecular therapy. Kidney Int. 47, 1462-1469.
78. [78] Sawai, K., Miyao, T., Takakura, Y. and Hashida, M. (1995) Renal disposition characteristics of oligonucleotides modified at terminal linkages in the perfused rat kidney. Antisense Res. Dev. 5, 279-287.
79. [79] Yoshida, M., Mahato, R.I., Kawabata, K., Takakura, Y. and Hashida, M. (1996) Disposition characteristics of plasmid DNA in the single-pass rat liver perfusion system. Pharm. Res. 13, 597-601.
80. [80] Leonetti, J.-P. and Leserman, L.D. (1993) Targeted delivery of oligonucleotides. In: S.T. Crooke and B. Lebleu (Eds.) Antisense Research and Applications, CRC Press, Boca Raton, FL, pp. 493-504.
81. [81] Wu, G.Y. and Wu, C.H. (1988) Receptor-mediated gene delivery and expression in vivo. J. Biol. Chem. 263, 14621-14624.
82. [82] Wagner, E., Zenke, M., Gotten, M., Beug, H. and Birnstiel, M.L. (1990) Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc. Natl. Acad. U.S.A. 87, 3410-3414.
83. [83] Findeis, M.A., Wu, C.H. and Wu, G.Y. (1994) Ligand-based carrier systems for delivery of DNA to hepatocytes. Methods Enzymol. 247, 341-351.
84. [84] Chen, J., Stickles, R.J. and Daichendt, K.A. (1994) Galactosylated histone-mediated gene transfer and expression. Hum. Gene Ther. 5, 429-435.
85. [85] Cotten, M., Laengle-Ranault, F., Kirlappos, H., Wagner, E., Mechtler, K., Zenke, M., Berg, H. and Birnstiel, M.L. (1991) Transferrin-polycalion mediated introduction of DNA into human leukemic cells: stimulation agents that affect survival of transfected DNA or modulate transferrin receptor levels. Proc. Natl. Acad, Sci. U.S.A. 87, 4033-4037.
86. [86] Bonfils, E., Mendes, C., Roche, A.-C., Monsigny, M. and Midoux, P. (1992) Uptake by macrophages of a biotinylated oligo-α-deoxythymidylate using mannosylated streptavidin. Bioconj. Chem. 3, 277-284.
87. [87] Ferkol, T., Kaetzel, C.S. and Davis, P.B. (1993) Gene transfer into respiratory epithelial cells by targeting the polymeric immunoglobulin receptor. J. Clin. Invest. 92, 2394-2400.
88. [88] Huckett, B., Ariatti, M. and Hawtrey, A.O. (1990) Evidence for targeted gene transfer by receptor-mediated endocytosis: Stable expression following insulin-directed entry of NEO in HepG2 cells. Biochem. Pharmacol. 40, 253-263.
89. [89] Strydom, S., Jaarsveld, P.V., Helden, E.V, Ariatti, M. and Hawtrey, A. (1993) Studies on the transfer of DNA into cells through use of avidin-polylysine conjugates complexed to biotinylated transferrin and DNA. J. Drug Target. 1, 165-174.
90. [90] Chen, J., Gamou, S., Takayanagi, A. and Shimizu, N. (1994) A novel gene delivery system using EGF receptor-mediated endocytosis. FEBS Lett. 338, 167-169.
91. [91] Cheng, P.-W. and Yin, W. (1994) Lectin conjugate-directed gene transfer to airway epithelial cells. Biochem. Biophys. Res. Commun. 205, 826-833.
92. [92] Bunnell, B.A., Askari, F.A. and Wilson, J.M. (1992) Targeted delivery of antisense oligonucleotides by molecular conjugates. Somatic Cell Mol. Genet. 16, 121-133.
93. [93] Reinis, M., Damkova, M. and Korec, E. (1993) Receptor-mediated transport of oligodeoxynucleotides into hepatic cells. J. Virol. Meth. 42, 99-106.
94. [94] Wu, G.Y. and Wu, C.H. (1992) Specific inhibition of hepatitis B viral gene expression in vitro by oligonucleotides. J. Biol. Chem. 267, 12436-12439.
95. [95] Bonfils, E., Depierreux, C., Midoux, P., Thuong, N.T., Monsigny, M. and Roche, A.C. (1992) Drug targeting: synthesis and endocytosis of oligonucleotide-neoglycoprotein conjugates. Nucleic Acids Res. 20, 4621-4629.
96. [96] Bonfils, E., Mendes, C., Roche, A.C., Monsigny, M. and Midoux, P. (1992) Uptake of macrophages of a biotinylated oligo α-deoxythymidylate by using mannosylated streptavidin. Bioconjugate Chem. 3, 277-284.
97. [97] Pardridge, W.M. and Boado, R.J. (1991) Enhanced cellular uptake of biotinylated antisense oligonucleotide or peptide mediated by avidin, a cationic protein. FEBS Lett. 288, 30-32.
98. [98] Boado, R.J. and Pardridge, W.M. (1994) Complete inactivalion of target mRNA by biotinylated antisense oligonucleotide-avidin conjugates. Bioconj. Chem. 5, 406-410.
99. [99] Citro, G., Perrotti, D., Cucco, C., D'Agnano, I., Sacchi, A., Zupi, G. and Calabretta, B. (1992) Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides. Proc. Natl. Acad. U.S.A. 89, 7031-7035.
100. [100] Citro, G., Szczylik, C., Ginpbbi, P., Zupi, G. and Calabretta, B. (1994) Inhibition of leukaemia cell proliferation by folic acid-polylysine-mediated introduction of c-myb antisense oligodeoxynucleotides into HL-60 cells. Br. J. Cancer 69, 463-467.
101. [101] Lu, X.-M., Fischman, A.J., Jyawook, S.L., Hendricks, K., Tompkins, R.G. and Yarmusch, M.L. (1993) Antisense DNA delivery in vivo: liver targeting by receptor-mediated uptake. J. Nuclear Med. 35, 269-275.
102. 32P]-labeled phosphodiester oligonucleotide coupled to a neutral avidin/monoclonal antibody conjugate. Drug Metab. Dispos. 23, 55-59.
103. [103] Pardridge, W.M., Boado, R.J. and Kang, Y.S. (1995) Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo. Proc. Natl. Acad. Sci. U.S.A. 92, 5592-5596.
104. [104] Stankovicks, J., Crane, A.N., Andrews, E., Wu, C.H., Wu, G.Y. and Ledley, F.D. (1994) Overexpression of human methylmalonyl CoA mutase in mice after in vivo gene transfer with asialoglycoprotein/polylysine/ DNA complexes. Hum. Gene Ther. 5, 1095-1104.
105. [105] Schlepper-Schäfer, J., Hülsman, D., Djovkar, A., Meyer, H.E., Herbertz, L., Kolb, H. and Kolb-Bachofen, V. (1986) Endocytosis via galactose receptors in vivo: Ligand size directs uptake by hepatocytes and/or liver macrophages. Exp. Cell Res. 165, 494-506.
106. [106] Perales, J.C., Ferkol, T., Beegen, H. and Ratnoff, O.D. (1994) Gene transfer in vivo: sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc. Natl. Acad. Sci. U.S.A. 91, 4086-4090.
107. [107] Takahashi, T., Yamaguchi, T., Kitamura, K., Noguchi, A., Honda, M. and Otsuji, E. (1993) Follow-up study of patients treated with monoclonal antibody-drug conjugate: Report of 77 cases with colorectal cancer. Jpn. J. Cancer Res. 84, 976-981.
108. [108] Maeda, H. (1991) SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Del. Rev. 6, 181-202.